Lavipharm (LAVI.AT) Stock Price

Lavipharm Price

CLOSED
1.48
​
Market closed

Revenue at Lavipharm has contracted by 6.6% per year over the past 19 years to 62.58 M EUR. Earnings per share have declined at 3.1% per year over the last 19 years. For Lavipharm, the net margin of 9.6% is up versus 4.3% a few years ago. At today's price the dividend yield works out to roughly 1.36%. The payout ratio is around 56% of earnings.

Lavipharm stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm business model & stock analysis

Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period.

Frequently asked questions about Lavipharm

The expected revenue of Lavipharm is 81.95 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Lavipharm is 6.75 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lavipharm is currently 36.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lavipharm stock.

The price-to-sales ratio (P/S) of Lavipharm is currently 3.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lavipharm stock.

The Eulerpool Quality Score for Lavipharm is 6/10.

The ISIN of Lavipharm is GRS246003008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Lavipharm is A3DSHM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Lavipharm is LAVI.AT. The ticker symbol is used to trade Lavipharm shares on the stock exchange.

Fair ValueTerminal
1.28 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
340,130.43 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Greece
Currency
EUR
Initial public offering
Nov 8, 1995
ISIN
GRS246003008
Cusip
X4816S132
Market capitalization
248.99 M EURMicro Cap
52-Week Range
PEG
1.14
P/E ratio
P/Ee 2026
36.90
P/Ee 2027
12.30
P/Ee 2028
8.68
P/Ee 2029
8.20
P/Ee 2030
7.77
P/S
P/Se
3.04
EV/EBIT
37.88
P/B Ratio
4.41
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
7.06 %
Dividend
Dividend yield
1.36 %
Est. Dividend Yield
1.36 %
Payout Ratio
56.39 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
1 year
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
5.00 %
Last updated Nov 16, 2026, 3:42 AM

Lavipharm Peer Group

Lavipharm FIGI

LAVI:GA · BBG000FRM981BXA0:GR · BBG000JT2RR4BXA0:GF · BBG000JT2T72BXA0:GB · BBG000JT2XZ2LAVI:XH · BBG000QX2JC1LAVI:XC · BBG000QX2JL1LAVI:XF · BBG000QX2K01LAVI:XE · BBG000QX2KV7LAVI:XL · BBG000QX2MQ9LAVI:XG · BBG000QX2MY0LAVI:XO · BBG000QX2N23LAVI:XA · BBG000QX2P19

All fundamentals and in-depth analysis of Lavipharm

Our stock analysis for Lavipharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lavipharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.